• Granitor Group startpage
  • Granitor companies
    • Granitor Electro
    • Granitor Miljöteknik
    • Granitor Systems
    • Granitor Properties
    • All the companies within the Granitor Group
  • Språk/Language
    • English
    • Svenska
    • Norsk
  • Our operations

    Our operations

    Solutions for now and the future

    OUR BUSINESS AREAS

    • Properties Development and management of commercial and residential properties
    • Contracting, consulting and services Installation, service and delivery systems within industry, construction and infrastructure
    • Investments Investments in pioneering technologies within cleantech and life sciences

    HOW WE WORK

    • Our responsibility We conduct responsible business for a better future
  • Our companies

    Our companies

    Companies in our group
    • Granitor Electro Contracting and service within electrical installations and mechanical maintenance
    • Granitor Miljöteknik Soil remediation and water treatment
    • Granitor Properties Development and management of commercial and residential properties
    • Granitor Systems Development of resource efficient systems for industrial plants

    Managed companies

    • Alucrom
    • BAC Group
    • Metalock Engineering
    • Nordic Mechanical Solutions
    • Read more about all our companies
  • Our responsibility
  • Career

    Career

    Career at Granitor
    • Work at Granitor
  • About Granitor

    About Granitor

    This is Granitor
    • Press
    • Economy
    • Management & organization
    • Our history
    • Midroc becomes Granitor
Contact us
  • Granitor
  • Our operations
  • Investments
  • Life science

Life science

In our investment portfolio, we have companies that develop solutions that previously were considered impossible, but now becomes more and more real.

Oblique Therapeutics

Oblique Therapeutics is a curiosity-driven, innovative biotech company with strong scientific acumen and drive for increasing the bandwidth of antibody therapeutics, focusing on pain and aggressive-metastatic cancer.

Read more about Oblique Therapeutics
  • Granitor
  • Our operations
  • Investments
  • Life science
Scroll to the top
{{ !expanded ? model.ReadMoreText : 'Hide' }}
{{ model.FactsHeading }}
{{fact.Label}}
{{fact.Text}}
{{ model.Contact.Heading }}
{{ model.Contact.Name }}
{{ model.Contact.Office }}
{{ model.Contact.Adress }}
{{ model.Contact.Phone }}
{{ model.Contact.Email }}
{{ !expanded ? model.ReadMoreText : 'Hide' }}
{{ model.FactsHeading }}
{{fact.Label}}
{{fact.Text}}
{{ model.Contact.Heading }}
{{ model.Contact.Name }}
{{ model.Contact.Office }}
{{ model.Contact.Adress }}
{{ model.Contact.Phone }}
{{ model.Contact.Email }}
{{ !expanded ? model.ReadMoreText : 'Hide' }}
{{ model.FactsHeading }}
{{fact.Label}}
{{fact.Text}}
{{ model.Contact.Heading }}
{{ model.Contact.Name }}
{{ model.Contact.Office }}
{{ model.Contact.Adress }}
{{ model.Contact.Phone }}
{{ model.Contact.Email }}
  • Integrity and cookie policy
  • Employee login
  • Whistleblowing system
Facebook LinkedIn Youtube